Form 4: Immix Biopharma Director Jane Buchan Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Jane Buchan was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.
Summary
- Director Jane Buchan acquired 6,250 restricted stock units (RSUs) on May 22, 2026.
- The director was also granted 12,500 stock options with an exercise price of $8.78.
- Following these transactions, the director's direct beneficial ownership of common stock increased to 28,705 shares.
- The equity grants were issued under the Issuer's 2021 Equity Incentive Plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Standard retention mechanism for board members via vesting schedules.
Negatives
- Potential for future dilution of existing shareholders upon the exercise of options and vesting of RSUs.
Risks
- Vesting is subject to the director's continued service with the company.
- Market price volatility may impact the future value of the granted options.
Future Outlook
The equity grants are subject to vesting schedules tied to the one-year anniversary of the grant or the 2027 Annual Meeting of stockholders, contingent upon continued service.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure leadership retention and alignment with corporate milestones.
Comparison to Industry Standards
- The use of 2021 Equity Incentive Plans is consistent with standard corporate governance practices for small-cap biotech firms.
- Vesting periods of one year for director equity are aligned with typical industry benchmarks for board compensation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of RSUs and stock options to a director under the 2021 Equity Incentive Plan. | 05/22/2026 | Increases director equity stake, aligning interests with shareholders. |
Stakeholder Impact
- Shareholders: Minor dilution impact upon future exercise/vesting.
- Director: Increased financial stake in company performance.
Next Steps
- Vesting of RSUs on the earlier of the one-year anniversary or the 2027 Annual Meeting.
- Vesting of stock options in monthly installments over 12 months.
Key Dates
| Date | Description |
|---|---|
| 05/22/2026 | Date of the equity grant transaction. |
| 05/22/2036 | Expiration date of the granted stock options. |
| 05/29/2026 | Date the Form 4 was signed and filed. |
Keywords
Immix Biopharma, IMMX, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.